Pay in 4 interest-free payments of $6.84 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for the treatment of type 2 diabetes mellitus and chronic weight management
Because the target is different, the experience can feel different
The first week on semaglutide guide covers what to expect during the initial period
Retatrutide acts on GLP-1, GIP, and glucagon receptors simultaneously, producing notable effects on gastric motility that may predispose some individuals to acid reflux and heartburn-type symptoms
Low testosterone is a natural part of aging
While GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists can benefit many patients with type 2 diabetes or obesity, certain individuals face elevated risk for gallbladder complications and require careful consideration before initiating therapy
